Galectin-3 in Ambulatory Patients With Heart Failure

Abstract

Background Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study. Methods and Results HF-ACTION was a randomized controlled trial of exercise training in patients with chronic heart failure due to left ventricular (LV) systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. Higher galectin-3 levels were associated with other measures of heart failure severity, including higher NYHA class, lower systolic blood pressure, higher creatinine, higher NTproBNP, and lower maximal oxygen consumption. In unadjusted analysis, there was a significant association between elevated galectin-3 levels and hospitalization-free survival (unadjusted hazard ratio = 1.14 per 3 ng/mL increase in galectin-3, P<0.0001). In multivariable modeling, the prognostic impact of galectin-3 was significantly attenuated by the inclusion of other known predictors and galectin-3 was no longer a significant predictor after the inclusion of NTproBNP. Conclusions Galectin-3 is elevated in ambulatory heart failure patients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP.

Is galectin-3 a promoter of ventricular dysfunction?

“…In this trial, galectin-3 levels correlated with the NYHA class, maximum oxygen consumption, systolic blood pressure and the risk for hospitalization or allcause mortality, in univariate analysis; however, the correlation was lost in multivariate analysis, when adjustments for NT-proBNP levels were made [66].…”

New possibilities of diagnostics and control of efficacy of drug therapy for chronic heart failure

“…В нашей работе была выявлена слабая корреляционная связь между уровнями NT-proBNP и галектина-3 плазмы (r=0,3; p=0,02) (табл. 2), что сопоставимо с результатами многоцентрового рандомизированного исследования HF-ACTION [12].…”

Прогностичне Значення Рівня Галектину-3 У Хворих З Гіпертрофічною Кардіоміопатією

“…СН III-IV ст. у больных с прогрессирующим течением забо-левания выявлялась более чем в 2 раза чаще -24,1 и 54,5 % соответственно в первой и второй группах неблагоприятных исходов [5]. В недавнем исследова-нии китайских ученых регрессионный анализ выявил высокую информативность Гал-3 как независимого предиктора смертности от всех причин и повторной госпитализации у больных с ИБС, осложненной СН.…”